As of January 2023, the X-waiver is no longer required to prescribe buprenorphine for opioid use disorder. Any references to the X-waiver no longer apply. The educational content on this site that offers CME meets the MATE Act requirements of 8 hours of training required for DEA certification.
As part of the DHCS MAT Expansion efforts, supplemental funds are directed to address the rising trend of stimulant use identified among patients across the state. UCLA ISAP launched the Stimulant Use Disorder Projects, which aim to understand patterns of use and risk for these substances, evaluate how programs are addressing polysubstance use, understand the current landscape of treatments for stimulant use disorder in publicly-funded specialty programs and primary care settings across California, and increase the uptake of evidence-based resources.
Specialty and primary care settings each have distinct patient flows, staffing configurations, and objectives, work cultures, and approaches to patient care. Given their distinct needs and distinct staffing, UCLA has developed three projects that will target multiple treatment settings that provide treatment to patients struggling with Stimulant Use Disorder:
Utilizing a Request for Application (RFA) mechanism, ten (10) SUD providers will have the opportunity to participate in a pilot project to enhance and improve the treatment experience of individuals with Stimulant Use Disorder. Selected programs will be trained and coached to deliver a manualized integrated, research-supported, multi-component approach (namely the TRUST* model) to enhance and improve the treatment experience of individuals with Stimulant Use Disorder.
The TRUST manual (Treatment and Recovery for Users of Stimulants) includes the following combined evidence-supported strategies:
*developed by Richard Rawson, Ph.D, Albert Hasson, MSW, Michael McCann, M.A., and Janice Stimson, PsyD.
Of the 10 awarded programs, UCLA will train program staff on the materials, resources, and evidence-based strategies that are responsive to current need, provide technical assistance and guidance as needed, and measure for feasibility and acceptability of the evidence-supported content. More details can be found in the RFA.
Advocates for Human Potential (AHP), in partnership with UCLA ISAP, will be the Administrative Entity on behalf of DHCS, to facilitate the RFA mechanism and issue the funds associated in this opportunity.
Notice of Awards released to 10 sites on January 29, 2021; Project Activities initiated on Feb 17, 2021 and activities will be staggered across two cohorts.
|
IMPORTANT DATES* RFA Release Date Informational Webinar Notice of Intent (Optional) Question of Submittal Deadline Application Deadline Projected Award Announcement First Intervention Training *The dates are subject to change, so please sign-up for updates to stay informed. |
|
UCLA Project Director: Sherry Larkins, Ph.D: SLarkins@mednet.ucla.edu
The first phase of this project will consist of exploratory and qualitative work conducting interviews and/or listening sessions with key stakeholders, thought leaders and provider champions in primary care settings. The objective of is to better understand the current clinical practices being used to address stimulant use in non-specialty settings, identify barriers and facilitators of adopting evidence-based practices, and discuss the training and supports needed to facilitate the uptake of evidence-based resources. Themes from these discussions will be analyzed using qualitative methods and used to inform training and quality/process improvement activities. The goal is to develop a toolkit or set of guidelines for clinical use in primary care settings, which will be assessed for feasibility and acceptability in phase 2 of this project.
UCLA Project Director: Sherry Larkins, Ph.D: SLarkins@mednet.ucla.edu
Similar to Project 2, the first phase of this project will consist of exploratory and qualitative work conducting interviews and/or listening sessions with key stakeholders, thought leaders and provider champions in primary care settings. The distinction in project 3 is that we will target primary care programs and providers who are X-waivered prescribers and currently prescribe medications for opioid use disorder (OUD) in primary care settings. The objective is to better understand the current clinical practices being used to address stimulant use among OUD patients in primary care settings, identify barriers and facilitators of adopting evidence-based practices, and discuss the training and supports needed to facilitate the uptake of evidence-based resources. Themes from these discussions will be analyzed using qualitative methods and used to inform training and quality/process improvement activities. The goal is to develop a toolkit or set of guidelines for clinical use in primary care settings, which will be assessed for feasibility and acceptability in phase 2 of this project.
UCLA Project Director: Sherry Larkins, Ph.D: SLarkins@mednet.ucla.edu